DENDRITICS works in collaboration with scientists working for cancer treatment and research. Some of DENDRITICS's monoclonal antibodies are utilized for diagnosis and prognosis studies as:

•DC-LAMP antibody, clone 1010E1.01, DDX0191:

 1.Human mature dendritic cells express DC-LAMP. Mature DC-LAMP+dendritic cells accumulation was shown in sentinel lymph node (SLN) with micrometastatic melanoma. Mature dendritic cells accumulation has a long-term protective effect.
Eliott B., et al., Clin. Cancer Res. 2007, 13, 3825-

 2.Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.
Dieu-Nosjean MC. et al., Journal of clinical Oncology 2008, 26, 4010-

 •BDCA-2 / CD303 antibody, clone 124B3.13, DDX0043:

Tumor CD4+CD56+CD123+/CD303+ cells are the malignant counterpart of pDCs. with Professor Berger courtesy

 •IL3-Ralpha antibody, clone 107D2.08, DDX0300:

A study on breast adenocarcinoma with DENDRITICS IL3-Ralpha /CD123 monoclonal antibody (DDX0300) has shown human pDCs CD123+ infiltration in these tumors.
Treilleux I., et al., Clin. Cancer Res. 2004, 10, 7466-

 with Bendriss-Vermare Nathalie courtesy.